Journal article icon

Journal article

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Abstract:

In vivo alemtuzumab reduces the risk of graft-versus-host disease (GVHD) and nonrelapse mortality after reduced intensity allogeneic transplantation. However, it also delays immune reconstitution, leading to frequent infections and potential loss of graft-versus-tumor responses. Here, we tested the feasibility of alemtuzumab dose deescalation in the context of fludarabine-melphalan conditioning and human leukocyte antigen (HLA)-identical sibling transplantation. Alemtuzumab was given 1-2 days...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Expand authors...
Journal:
Blood
Volume:
116
Issue:
16
Pages:
3080-3088
Publication date:
2010-10-05
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
URN:
uuid:964bc148-36fd-4027-8977-fc3d5568fb7e
Source identifiers:
244893
Local pid:
pubs:244893

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP